AstraZeneca and Oxford University's COVID-19 vaccine shows better result in elderly: Study

A new study published in Lancet Journal shows that potential COVID-19 vaccine developed by AstraZeneca Plc and Oxford University enables a strong immune response in older ults. As a part of study, healthy ults d 18 years and older were enrolled at two UK clinical research facilities. This was done in an escalation manner. People were divided into groups of 18–55 years, 56–69 years, and 70 years and older immugenicity subgroups.

A new revelation

As first step, participants were recruited to a low-dose cohort and all groups were randomly assigned to receive eir intramuscular ChOx1 nCoV-19 (2·2 × 1010 virus particles) or a control vaccine, MenACWY. However, this was done using block randomisation. Certain ratios were also allotted. Late in October, after having security and safety of trials reviewed by US Food and Drug ministration, AstraZeneca resumed its major clinical trials for experimental COVID-19 vaccines. AstraZeneca h to pause trials after  serious verse reaction (SAE) was detected in volunteers. Also, AstraZeneca anunced that  FDA regulators h approved resumption for Oxford coronavirus vaccine in US, UK, Brazil, South Africa, and Japan confirming that it was safe. 

Re: Oxford University COVID-19 Vaccine ‘encouraging’ For Older Groups

(Study profile for low-dose (A) and standard-dose (B) cohorts. Im Credits: Lancet.com)

main objective of study was to assess safety and cellular immugenicity of a single-dose and two-dose schedule in ults older than 55 years. During study, 560 participants were enrolled between May 30 and Aug 8, 2020. Out of this, 160 were d 18–55 years, ar 160 were d 56–69 years and remaining 240 were d 70 years and older. study said, “Seven participants did t receive boost dose of ir assigned two-dose regimen, one participant received incorrect vaccine, and three were excluded from immugenicity analyses due to incorrectly labelled samples. 280 (50%) of 552 analysable participants were female”. 

Re: Australia's CSL Limited Begins Production Of AstraZeneca-Oxford COVID-19 Vaccine Candidate

It was n concluded that ChOx1 nCoV-19 works better in older ults than in younger ults. Also, study suggests that it has similar immugenicity across all groups. study furr said that ‘furr assessment of efficacy of this vaccine is warranted in all groups and individuals with comorbidities’.

Re: COVID-19: AstraZeneca, Johnson & Johnson Resume Clinical Trials Of Vaccine After Pause

Also Re: AstraZeneca Failed To Deliver COVID-19 Vaccine Doses To UK On Promised Date: British Govt

(Im Credits: PTI)